|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2-3
|
|
pubmed:dateCreated |
2005-8-9
|
|
pubmed:abstractText |
The HER2/neu proto-oncogene encodes a transmembrane receptor protein involved in the development and progression of the majority of cancers. Prior studies have shown that HER2/neu oncogene is overexpressed in approximately 15-30% of ovarian carcinomas. However findings regarding the overexpression and prognosis are still conflicting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2005 S. Karger AG, Basel.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
154-61
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16020953-Adult,
pubmed-meshheading:16020953-Aged,
pubmed-meshheading:16020953-Aged, 80 and over,
pubmed-meshheading:16020953-Carcinoma,
pubmed-meshheading:16020953-Disease Progression,
pubmed-meshheading:16020953-Female,
pubmed-meshheading:16020953-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16020953-Humans,
pubmed-meshheading:16020953-Middle Aged,
pubmed-meshheading:16020953-Multivariate Analysis,
pubmed-meshheading:16020953-Ovarian Neoplasms,
pubmed-meshheading:16020953-Predictive Value of Tests,
pubmed-meshheading:16020953-Prognosis,
pubmed-meshheading:16020953-Receptor, erbB-2,
pubmed-meshheading:16020953-Survival Analysis,
pubmed-meshheading:16020953-Tumor Markers, Biological,
pubmed-meshheading:16020953-Up-Regulation
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study.
|
|
pubmed:affiliation |
Academic Department of Medical Oncology, National Cancer Research Institute, Genoa, Italy.
|
|
pubmed:publicationType |
Journal Article
|
